Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines

R. M. Mohammad, A. Al-Katib, George Pettit, L. L. Sensenbrenner

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Bryostatin 1 (Bryo1), a macrocyclic lactone and a protein kinase C activator, is extracted and purified from the marine bryozoan Bugula neritina. In this study we describe its effect on morphology, surface immunophenotype, acid phosphatase (AcP), tartrate-resistant acid phosphatase (TRAP), proliferation and cell cycle of non-Hodgkin's B-lymphoma cell lines representing four differentiation stages. Except for the WSU-BL, a high-grade SCNCL, all other cell lines showed obvious changes in their morphology when treated with 200 nM Bryol. Phenotypically, a dramatic decrease of CD10 and induction of CD11c and BL7 on some cell lines consistent with further B-cell differentiation was seen. The lines in control cultures showed variable expression of AcP and TRAP. Following treatment with Bryol, there was a general increase in AcP expression except in WSU-BL line. WSU-FSCCL and WSU-DLCL were TRAP-negative but became TRAP-positive when treated with Bryol. Cell growth and cycle analysis during treatment of different cell lines revealed evidence of strong, moderate, or no growth inhibition by Bryol compared with control cultures. Our results indicate that Bryol shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high-grade SCNCL. Since Bryo1 does not have tumor-promoting activity, it has a potential therapeutic role as a B-cell differentiating agent.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalLeukemia Research
Volume17
Issue number1
DOIs
StatePublished - 1993

Fingerprint

Non-Hodgkin's Lymphoma
Acid Phosphatase
Cell Line
Cell Cycle
B-Lymphocytes
Lactones
Growth
Protein Kinase C
Cell Differentiation
Tartrate-Resistant Acid Phosphatase
bryostatin 1
Neoplasms
Therapeutics

Keywords

  • B-cell lymphoma
  • bryostatin 1
  • differentiation
  • protein kinase C

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines. / Mohammad, R. M.; Al-Katib, A.; Pettit, George; Sensenbrenner, L. L.

In: Leukemia Research, Vol. 17, No. 1, 1993, p. 1-8.

Research output: Contribution to journalArticle

Mohammad, R. M. ; Al-Katib, A. ; Pettit, George ; Sensenbrenner, L. L. / Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines. In: Leukemia Research. 1993 ; Vol. 17, No. 1. pp. 1-8.
@article{58e009dde22146d2ac7e632d0fbd68f4,
title = "Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines",
abstract = "Bryostatin 1 (Bryo1), a macrocyclic lactone and a protein kinase C activator, is extracted and purified from the marine bryozoan Bugula neritina. In this study we describe its effect on morphology, surface immunophenotype, acid phosphatase (AcP), tartrate-resistant acid phosphatase (TRAP), proliferation and cell cycle of non-Hodgkin's B-lymphoma cell lines representing four differentiation stages. Except for the WSU-BL, a high-grade SCNCL, all other cell lines showed obvious changes in their morphology when treated with 200 nM Bryol. Phenotypically, a dramatic decrease of CD10 and induction of CD11c and BL7 on some cell lines consistent with further B-cell differentiation was seen. The lines in control cultures showed variable expression of AcP and TRAP. Following treatment with Bryol, there was a general increase in AcP expression except in WSU-BL line. WSU-FSCCL and WSU-DLCL were TRAP-negative but became TRAP-positive when treated with Bryol. Cell growth and cycle analysis during treatment of different cell lines revealed evidence of strong, moderate, or no growth inhibition by Bryol compared with control cultures. Our results indicate that Bryol shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high-grade SCNCL. Since Bryo1 does not have tumor-promoting activity, it has a potential therapeutic role as a B-cell differentiating agent.",
keywords = "B-cell lymphoma, bryostatin 1, differentiation, protein kinase C",
author = "Mohammad, {R. M.} and A. Al-Katib and George Pettit and Sensenbrenner, {L. L.}",
year = "1993",
doi = "10.1016/0145-2126(93)90134-7",
language = "English (US)",
volume = "17",
pages = "1--8",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Differential effects of bryostatin 1 on human non-hodgkin's B-lymphoma cell lines

AU - Mohammad, R. M.

AU - Al-Katib, A.

AU - Pettit, George

AU - Sensenbrenner, L. L.

PY - 1993

Y1 - 1993

N2 - Bryostatin 1 (Bryo1), a macrocyclic lactone and a protein kinase C activator, is extracted and purified from the marine bryozoan Bugula neritina. In this study we describe its effect on morphology, surface immunophenotype, acid phosphatase (AcP), tartrate-resistant acid phosphatase (TRAP), proliferation and cell cycle of non-Hodgkin's B-lymphoma cell lines representing four differentiation stages. Except for the WSU-BL, a high-grade SCNCL, all other cell lines showed obvious changes in their morphology when treated with 200 nM Bryol. Phenotypically, a dramatic decrease of CD10 and induction of CD11c and BL7 on some cell lines consistent with further B-cell differentiation was seen. The lines in control cultures showed variable expression of AcP and TRAP. Following treatment with Bryol, there was a general increase in AcP expression except in WSU-BL line. WSU-FSCCL and WSU-DLCL were TRAP-negative but became TRAP-positive when treated with Bryol. Cell growth and cycle analysis during treatment of different cell lines revealed evidence of strong, moderate, or no growth inhibition by Bryol compared with control cultures. Our results indicate that Bryol shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high-grade SCNCL. Since Bryo1 does not have tumor-promoting activity, it has a potential therapeutic role as a B-cell differentiating agent.

AB - Bryostatin 1 (Bryo1), a macrocyclic lactone and a protein kinase C activator, is extracted and purified from the marine bryozoan Bugula neritina. In this study we describe its effect on morphology, surface immunophenotype, acid phosphatase (AcP), tartrate-resistant acid phosphatase (TRAP), proliferation and cell cycle of non-Hodgkin's B-lymphoma cell lines representing four differentiation stages. Except for the WSU-BL, a high-grade SCNCL, all other cell lines showed obvious changes in their morphology when treated with 200 nM Bryol. Phenotypically, a dramatic decrease of CD10 and induction of CD11c and BL7 on some cell lines consistent with further B-cell differentiation was seen. The lines in control cultures showed variable expression of AcP and TRAP. Following treatment with Bryol, there was a general increase in AcP expression except in WSU-BL line. WSU-FSCCL and WSU-DLCL were TRAP-negative but became TRAP-positive when treated with Bryol. Cell growth and cycle analysis during treatment of different cell lines revealed evidence of strong, moderate, or no growth inhibition by Bryol compared with control cultures. Our results indicate that Bryol shows differentiation effects on low-grade FSCCL, intermediate-grade FLCL and high-grade DLCL, and stimulatory or no effect on high-grade SCNCL. Since Bryo1 does not have tumor-promoting activity, it has a potential therapeutic role as a B-cell differentiating agent.

KW - B-cell lymphoma

KW - bryostatin 1

KW - differentiation

KW - protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=0027474602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027474602&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(93)90134-7

DO - 10.1016/0145-2126(93)90134-7

M3 - Article

C2 - 8429674

AN - SCOPUS:0027474602

VL - 17

SP - 1

EP - 8

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -